On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Stocks To Buy Now


Geyser Brands Inc. (TSX.V: GYSR) Strengthens Leadership with Key Appointments

  • Seasoned life sciences executive Dr. Bin Huang has been appointed to the Geyser board of directors
  • Chartered Professional Account Gordon Clissold has been named chief executive officer
  • Geyser Brands is entering into a definitive agreement for the acquisition of Solace Management Group, which will broaden the company’s range of CBD- and hemp-based products

Geyser Brands Inc. (TSX.V: GYSR), a leading consumer health care company based in Vancouver, British Columbia, builds health-based hemp CBD consumer products in the worldwide nutraceutical, cosmetics, food & beverage and pet sectors. Recent pivotal appointments to Geyser Brand’s leadership team are expected to strengthen the company’s position and bring valued oversight to its ongoing development, as noted in a news release (http://ibn.fm/ElFjT).

Joining the board of directors is Dr. Bin Huang, a seasoned life sciences executive with experience in strategy and new business development, financing and public markets, corporate governance and operations management in North America and Asia. She most recently served as CEO of Emerald Health Therapeutics Inc. and has held senior management roles in both startups and Fortune 500 corporations. Huang holds a PhD in plant cell biology from the University of East Anglia, UK, and an MBA from the University of Toronto, Canada.

“The board of directors are extremely pleased that Dr. Huang has accepted our offer to join our growing company” Brad Kersch, chairman of the board, stated in a news release. “Her depth of experience in life sciences and her leadership demonstrated in the corporate world, particularly in the cannabis industry, will provide unparalleled value and oversight to the company’s development.”

Chartered Professional Accountant Gordon Clissold will take the position of chief financial officer, effective immediately, while Jennifer Hanson was recently named as corporate secretary. Clissold has over 20 years of experience as an operational and financial manager for both public and private companies and is a past president of the Certified General Accountants of BC.

“Gordon brings tremendous experience and added bench strength in both operational and financial management and we are very pleased he’s agreed to join the Geyser executive team,” Geyser Brands CEO Andreas Thatcher added.

The company also recently announced a significant advancement toward achieving its long-term vision of manufacturing premier CBD products, including tinctures and supplements. According to a news release (http://ibn.fm/pSliY), a coveted Health Canada standard processing license was awarded to the company’s wholly owned licensed producer, 0957102 B.C. Ltd. dba Apothecary Botanicals.

“This is a huge milestone for Geyser Brands and something that we have been working toward for many months,” Thatcher stated in the release. “The license allows us to add value to existing consumer health care brands by providing them the platform to add CBD. It also reflects our business model to focus our licensed producer on delivering scale through manufacturing and distribution. I wish to congratulate the team at Apothecary Botanicals and Geyser for all the hard work in obtaining this license. We are moving forward full steam with our vision and there is plenty more to come in the future.”

An earlier announced strategic acquisition of Solace Management Group Inc. is expected to add to Geyser Brands’ growing portfolio, establishing the company as a leading provider of health-focused CBD and hemp products (http://ibn.fm/yTJVU).

For more information, visit the company’s website at www.GeyserBrands.com

NOTE TO INVESTORS: The latest news and updates relating to GYSR are available in the company’s newsroom at http://ibn.fm/GYSR

From Our Blog

Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Helomics Leverages Cutting-Edge Tech and Datasets to Improve Cancer Outcomes

May 22, 2020

POAI subsidiary Helomics helps oncologists individualize cancer treatment using patient-derived tumor models to improve outcomes Helomics’ tumor genomic and drug response database is one of the largest in the world with over 150,000 tumors across 137 cancer types Expected CAGR of 10.3% from 2018-2024 for oncology segment of precision medicine industry The relationship between a […]

Rotate your device 90° to view site.